28 September 2020 - In 2019 and early 2020, drug pricing in the United States was a top concern of the public and therefore of politicians.
President Trump, the moderate Democrats, the progressive Democrats, and some Republicans competed to denounce louder and regulate more substantially the manner by which pharmaceutical firms set their prices.
With the advent of the coronavirus disease 2019 (COVID-19) pandemic, all the momentum was lost, and no major legislation was passed. The attention has shifted to finding therapies and vaccines to treat and prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and the US public wants more innovation, more manufacturing capacity, and more access for all. Only the usual industry critics are publicly concerned about price.